$HYPR

Hyperfine, Inc.

CIK:0001833769|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Sales
Total sales	$ 3,904	$ 2,696	$ 7,807	$ 4,833
Cost of sales
Total cost of sales	1,924	1,368	3,848	2,622
Gross profit	1,980	1,328	3,959	2,211
Operating Expenses:
Research and development	3,865	4,541	7,710	9,578
General and administrative	3,907	3,859	8,037	8,067
Sales and marketing	2,677	2,523	5,239	5,063
Total operating expenses	10,449	10,923	20,986	22,708
Loss from operations	(8,469)	(9,595)	(17,027)	(20,497)
Interest income	272	239	526	556
Interest expense	(533)	0	(616)	0
Change in Fair Value of Warrant Liabilities	(571)	46	(812)	1,664
Other income (expense), net	3	85	8	(366)
Loss before provision for income taxes	(9,298)	(9,225)	(17,921)	(18,643)
Provision for income taxes	0	0	0	0
Net loss and comprehensive loss	$ (9,298)	$ (9,225)	$ (17,921)	$ (18,643)
Net loss per common share attributable to common stockholders, basic	$ (0.09)	$ (0.12)	$ (0.18)	$ (0.24)
Net loss per common share attributable to common stockholders, diluted	$ (0.09)	$ (0.12)	$ (0.18)	$ (0.24)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic	99,797,156	78,077,118	98,751,951	76,893,733
Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted	99,797,156	78,077,118	98,751,951	76,893,733
Device
Sales
Total sales	$ 3,170	$ 2,128	$ 6,427	$ 3,650
Cost of sales
Total cost of sales	1,603	1,097	3,249	2,082
Service
Sales
Total sales	734	568	1,380	1,183
Cost of sales
Total cost of sales	$ 321	$ 271	$ 599	$ 540

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Dec. 31, 2025
Cash flows from operating activities:
Net loss			$ (17,921)	$ (18,643)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	$ 264	$ 283	538	512
Stock-based compensation expense			1,550	1,492
Loss on disposal of property and equipment, net			6	0
Change in fair value of warrant liabilities	571	(46)	812	(1,664)
Amortization of debt discount and issuance costs			129
Other			16	15
Changes in assets and liabilities:
Accounts receivable, net			1,037	899
Unbilled receivables			(304)	457
Inventory			274	733
Prepaid expenses and other current assets			(669)	(749)
Other long term assets			170	(34)
Accounts payable			(1,603)	1,339
Deferred grant funding			349	130
Deferred revenue			223	(230)
Due to related parties			11	(2)
Accrued expenses and other current liabilities			(897)	(1,404)
Operating lease liabilities, net			3	(10)
Net cash used in operating activities			(16,276)	(17,159)
Cash flows from investing activities:
Purchases of property and equipment			(272)	(992)
Net cash used in investing activities			(272)	(992)
Cash flows from financing activities:
Proceeds from issuance of debt, net			13,641
Proceeds from exercise of stock options			254	37
Net cash provided by financing activities			25,270	6,056
Net increase (decrease) in cash and cash equivalents and restricted cash			8,722	(12,095)
Cash, cash equivalents and restricted cash, beginning of period			36,042	37,673	$ 25,578
Cash, cash equivalents and restricted cash, end of period	44,764	25,578	44,764	25,578	44,764
Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets
Cash and cash equivalents	43,458	25,420	43,458	25,420	43,458	$ 35,085
Restricted cash	1,306	158	1,306	158	1,306
Total cash, cash equivalents and restricted cash	$ 44,764	$ 25,578	44,764	25,578	$ 44,764	$ 36,042
Supplemental disclosure of noncash information:
Issuance of warrants in connection with Loan Agreement, net			495
Initial measurement of warrant liabilities				2,858
Unpaid purchase of property and equipment			5	86
Noncash acquisition of fixed assets			27
Unpaid debt issuance and financing costs			15	2
Class A Common Stock \| At-the-market Offering Program
Cash flows from financing activities:
Gross proceeds from issuance of common stock			$ 11,375	835
Class A Common Stock \| February 2025 Offering
Cash flows from financing activities:
Gross proceeds from issuance of common stock				$ 5,184

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
CURRENT ASSETS:
Cash and cash equivalents	$ 43,458	$ 35,085
Restricted cash	1,306	957
Accounts receivable, less allowance of $495 and $1,372 as of June 30, 2026 and December 31, 2025, respectively	4,217	5,254
Unbilled receivables	1,572	1,268
Inventories	6,789	7,090
Prepaid expenses and other current assets	1,899	1,255
Total current assets	59,241	50,909
Property and equipment, net	2,262	2,549
Other long term assets	1,496	1,804
Total assets	62,999	55,262
CURRENT LIABILITIES:
Accounts payable	2,422	4,051
Deferred grant funding	1,306	957
Deferred revenue	1,661	1,544
Accrued expenses and other current liabilities	4,179	5,130
Total current liabilities	9,629	11,732
Long-term debt, net	13,235	0
Warrant liabilities	2,542	1,730
Long term deferred revenue	835	729
Other noncurrent liabilities	0	66
Total liabilities	26,241	14,257
COMMITMENTS AND CONTINGENCIES (NOTE 14)
STOCKHOLDERS' EQUITY:
Additional paid-in capital	384,684	371,011
Accumulated deficit	(347,937)	(330,016)
Total stockholders' equity	36,758	41,005
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	62,999	55,262
Related Party
CURRENT LIABILITIES:
Due to related parties	61	50
Class A Common Stock
STOCKHOLDERS' EQUITY:
Common stock	9	8
Class B Common Stock
STOCKHOLDERS' EQUITY:
Common stock	$ 2	$ 2